Please login to the form below

Not currently logged in
Email:
Password:

medicines access

This page shows the latest medicines access news and features for those working in and with pharma, biotech and healthcare.

GW Pharma's cannabis-based medicine to be tested in dementia

GW Pharma's cannabis-based medicine to be tested in dementia

Meanwhile, there have been some movements that suggest access to cannabis-based medicines could be easier to access within the UK.

Latest news

  • Industry aghast as EU Parliament backs biosimilar rule change Industry aghast as EU Parliament backs biosimilar rule change

    Our industry is extremely concerned that the proposal for the SPC manufacturing waiver will put patient access to medical innovation, highly killed jobs and investment at risk,” writes Oschmann. ... while stimulating greater access to medicines at

  • UK patient activist group takes aim at Orkambi patent UK patient activist group takes aim at Orkambi patent

    Pressure is rising on Vertex on access to its cystic fibrosis (CF) drug Orkambi in the UK, with an MP today calling for the government to bypass its patent and provide ... Vertex issued a statement on Friday, saying it was “determined to find a

  • End to middlemen rebates a major shift in US drug pricing End to middlemen rebates a major shift in US drug pricing

    Representatives of pharmacy benefit manager companies were  less pleased, saying the changes could impact access to medicines for Medicare users. ... The changes fulfil promises made by President Trump last year as part of his medicines pricing

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    Narasimhan is pushing the company towards a tighter focus on the most innovative medicines and leadership in digital innovation. ... Vas Narasimhan commented: "In 2018 we reimagined Novartis. We took major steps towards becoming a medicines company that

  • European Medicines Agency departs London ahead of Brexit European Medicines Agency departs London ahead of Brexit

    That list includes public health issues including the availability of medicines – for example by tackling the threat of drug shortages – and antimicrobial resistance (AMR), as well as ensuring “timely access to ... Novartis also urges NHS trusts

More from news
Approximately 4 fully matching, plus 407 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 79 partially matching documents found.

Latest appointments

  • Pfizer’s Alan Maine moves to Edelman Pfizer’s Alan Maine moves to Edelman

    Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... During his time at Pfizer, Maine also

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate

  • Inceptua Medicines Access appoints senior new-hires Inceptua Medicines Access appoints senior new-hires

    Multipharma’s new speciality business unit, Inceptua has appointed Ruth Rostron as its new senior project manager, a role that will see her focus on design and implementation of medicines access

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. ... I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”.

  • Takeda UK & Ireland appoints market access director Takeda UK & Ireland appoints market access director

    Takeda UK &Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm's new US-based global pricing, market access and health ... He also brings experience form Boehringer Ingelheim, where he

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

  • New opportunities in emerging markets

    This growth is set to continue. In parallel, we are seeing an increased focus among emerging market governments on public healthcare reform: expanding their populations’ access to medicines by establishing universal ... Greater purchasing power and

  • Training the next generation of biotech leaders

    The goal is to try and accelerate access to these medicines by reducing the time taken to learn how to manufacture them. ... It would be nice to think that in the next ten to fifteen years, we’ll see a pipeline of new medicines emerging off the back of

  • OPEN Access Consulting

    OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar introduction &defence.

  • Unique forum will unite NHS and industry to drive innovation

    HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare. ... and med tech sectors to work more closely with the NHS, to maximise value for money while

  • Medicines personalised for Tom, Dick and Harry

    Dorothy may have finally got home to Kansas, but are we doomed to keep following the Yellow Brick Road? If the Wicked Witch of the East’s ruby slippers had been several sizes smaller, would Dorothy have been destined to remain in the Land of Oz?

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics